BRE-13: Mediterranean Diet (BRE-13)
BRE-13: Mediterranean Diet-A Presurgical Window of Opportunity Trial Among Women With Breast Cancer
Explore the effect of MedDiet vs. Usual Diet on circulating and breast tumor fatty acid profiles. The investigators aim to examine impact on tumor biology in newly diagnosed participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Dietary supplement: Explore the effect of MedDiet vs. Usual Diet on Fatty Acid Profile
- Diagnostic test: Explore the effect of MedDiet vs. Usual Diet on Breast Tumor Tissue
- Diagnostic test: Explore the effect of MedDiet vs. Usual Diet on Lipids
- Diagnostic test: Explore the effect of MedDiet vs. Usual Diet on tumor tissue expression
Detailed Description
Conduct a 3-week presurgical window trial among 30 women with stage I-III luminal breast cancer. Participants will be randomized 1:1 to a controlled MedDiet or an enhanced usual-care control. This study will generate critical translational data on how dietary fat composition influences tumor metabolism and immune response, informing future diet-based cancer interventions.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lisa Marie Tussing-Humphreys, Ph.D.
- Phone Number: 312 355 5521
- Email: tussing@uic.edu
Study Contact Backup
- Name: Meredith Russell
- Phone Number: 312 355 5112
- Email: mrussel3@uic.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois at Chicago Campus
-
Contact:
- Meredith Russell, BS
- Phone Number: 312 355 5112
- Email: mrussel3@uic.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years;
- Newly diagnosed stage I-III luminal breast cancer
- Planned surgical resection at UI Health
- Ability to speak, read, write, and understand English
- A Mediterranean Eating Pattern for Americans (MEPA-III) score <13 indicating that they do not currently follow a MedDiet;
- ECOG performance status of 0 or 1.
Exclusion Criteria:
- Currently following a MedDiet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a MedDiet;
- Lack of access to a space to safely store and reheat foods items;
- Living in facility that provides meals;
- Chronic CKD stage 3+ or currently receiving dialysis treatment;
- History of GI surgery involving removal of part of the stomach or intestines;
- Type 1 or Type 2 diabetes;
- Autoimmune or Inflammatory disease or immunocompromised; and
- Cachexia.
We will not exclude other neoadjuvant treatments. Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant or breastfeeding women Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Med Diet
Mediterranean Diet (MedDiet) is a dietary pattern characterized by a low intake of saturated fats and a high intake of unsaturated fats, with olive oil as the primary culinary fat (7, 8). |
Fatty acid profile (chain length and degree of saturation) in circulation of blood, tumor tissue, and tumor interstitial fluid. Fatty acid profile (chain length and degree of saturation) in breast tumor tissue. Lipid availability in blood, tumor tissue, and tumor interstitial fluid. Tumor tissue will explore the effect of MedDiet vs. Usual Diet on tumor proliferation (Ki67) and expression of NK and CD8 T cells and chylomicrons (Apo48 staining). |
|
No Intervention: Usual Diet
Dietary fat and cancer has been conducted in preclinical models of diet-induced obesity, where high-fat diets promote tumor growth |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Aim 1a
Time Frame: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in blood. |
3 weeks
|
|
Aim 1b
Time Frame: 3 weeks
|
Lipid availability in blood, tumor tissue, and interstitial fluid. |
3 weeks
|
|
Aim 1c
Time Frame: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in breast tumor tissue, |
3 weeks
|
|
Aim 2a
Time Frame: 3 weeks
|
peripheral blood monocyte cells from the electronic health record. |
3 weeks
|
|
Aim 2b
Time Frame: 3 weeks
|
Tumor tissue will explore the effects on tumor proliferation (Ki67) cells. |
3 weeks
|
|
Aim 2c
Time Frame: 3 weeks
|
Tumor tissue will explore the effects on expression of NK cells. |
3 weeks
|
|
Aim 2d
Time Frame: 3 weeks
|
Tumor tissue will explore the effects on CD8 T cells(immunohistochemistry) cells. |
3 weeks
|
|
Aim 2e
Time Frame: 3 weeks
|
Tumor tissue will explore the effects on chylomicrons (Apo48 staining) cells. |
3 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory aim a
Time Frame: 3weeks
|
Stool will be used to analyze gut microbiome changes using shotgun bioinformatics and downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim b
Time Frame: 3weeks
|
Stool will be used to analyze downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim c
Time Frame: 3weeks
|
Stool will be used to analyze metabolic changes among the two study arms. |
3weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lisa Marie Tussing-Humphreys, Ph.D, University of Illinois Chicago Campus
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-0573
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.